Eli Lilly and Company (NYSE:LLY) Shares Sold by Jacobs & Co. CA

Jacobs & Co. CA lowered its position in Eli Lilly and Company (NYSE:LLY) by 6.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,560 shares of the company’s stock after selling 1,874 shares during the quarter. Eli Lilly and Company accounts for approximately 1.4% of Jacobs & Co. CA’s holdings, making the stock its 24th biggest holding. Jacobs & Co. CA’s holdings in Eli Lilly and Company were worth $11,987,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Norges Bank acquired a new position in Eli Lilly and Company in the 4th quarter worth $3,416,206,000. Moneta Group Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 102,752.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after buying an additional 5,440,731 shares in the last quarter. Morgan Stanley lifted its holdings in Eli Lilly and Company by 44.1% in the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in Eli Lilly and Company by 316.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock worth $217,569,000 after buying an additional 1,850,187 shares in the last quarter. Finally, Mizuho Markets Americas LLC lifted its holdings in Eli Lilly and Company by 2,882.6% in the 1st quarter. Mizuho Markets Americas LLC now owns 1,765,702 shares of the company’s stock worth $18,090,000 after buying an additional 1,706,502 shares in the last quarter. Institutional investors and hedge funds own 81.38% of the company’s stock.

Eli Lilly and Company Trading Down 0.9 %

Shares of NYSE:LLY opened at $570.65 on Monday. The company has a 50 day moving average of $512.56 and a 200-day moving average of $439.28. The firm has a market cap of $541.72 billion, a P/E ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating the consensus estimate of $1.98 by $0.13. The business had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the business earned $1.25 earnings per share. As a group, analysts anticipate that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were given a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a dividend yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 107,022 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total value of $49,153,064.16. Following the transaction, the insider now owns 101,248,810 shares in the company, valued at approximately $46,501,553,456.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 107,022 shares of the stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the transaction, the insider now owns 101,248,810 shares in the company, valued at approximately $46,501,553,456.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the sale, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,010,309 shares of company stock worth $21,095,701,670. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on LLY shares. UBS Group boosted their target price on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the stock a “buy” rating in a research report on Wednesday, May 24th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 8th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $630.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 5th. Finally, Barclays boosted their target price on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $532.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.